| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2013/035 | ||
|---|---|---|---|
| Date of filing | 15/07/2013 | ||
| Notification of Application Published | 14/08/2013 | ||
| Status | Rejected | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
NOVO NORDISK A/S Novo Alle 2880 Bagsvaerd DENMARK |
||
| Patent Number | 2107069 | ||
| Title of Invention | Novel insulin derivatives | ||
| Date of Expiry of Patent | 21/07/2024 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Combinatin of insulin degludec and insulin aspart in all its forms as they are protected by the basic patents | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/12/806/001,004,005,007 and 008 | ||
| Authorisation Date | 21/01/2013 | ||
| Identity of Product Authorised | Ryzodeg-insulin degludec and insulin aspart | ||
| Address for Service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||
| Renewal Fees | |||
| 18/07/2013 | Request for grant a Supplementary Protection Certificate filed on 15/07/2013, numbered 2013/035. | ||
| 21/12/2018 | Request for grant of Supplementary Protection Certification No. 2013/035 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||
| 24/03/2021 | Written grounds of decision issued on 14 January 2019. | ||